167 related articles for article (PubMed ID: 10634132)
1. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
Dalén P; Dahl ML; Eichelbaum M; Bertilsson L; Wilkinson GR
Pharmacogenetics; 1999 Dec; 9(6):697-706. PubMed ID: 10634132
[TBL] [Abstract][Full Text] [Related]
2. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461
[TBL] [Abstract][Full Text] [Related]
3. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
4. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
5. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.
Dalén P; Dahl ML; Bernal Ruiz ML; Nordin J; Bertilsson L
Clin Pharmacol Ther; 1998 Apr; 63(4):444-52. PubMed ID: 9585799
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
7. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Dalén P; Dahl M; Andersson K; Bertilsson L
Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
[TBL] [Abstract][Full Text] [Related]
9. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
[TBL] [Abstract][Full Text] [Related]
10. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
11. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.
Weerasuriya K; Jayakody RL; Smith CA; Wolf CR; Tucker GT; Lennard MS
Br J Clin Pharmacol; 1994 Nov; 38(5):466-70. PubMed ID: 7893590
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
15. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
Wennerholm A; Johansson I; Massele AY; Lande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL
Pharmacogenetics; 1999 Dec; 9(6):707-14. PubMed ID: 10634133
[TBL] [Abstract][Full Text] [Related]
16. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
17. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
19. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
Wennerholm A; Dandara C; Sayi J; Svensson JO; Abdi YA; Ingelman-Sundberg M; Bertilsson L; Hasler J; Gustafsson LL
Clin Pharmacol Ther; 2002 Jan; 71(1):77-88. PubMed ID: 11823760
[TBL] [Abstract][Full Text] [Related]
20. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
